Lymphoma, Large B-Cell, Diffuse

The supplied grounding does not support a specific cause or aetiology for diffuse large B-cell lymphoma. One review notes that novel genetic classification systems are being used to guide individualized treatment, but it does not establish a single causal mechanism. EBV is mentioned only in a broader review of EBV-related cancers and is not specifically linked here to this disease.

The disease arises from malignant transformation of B cells at a midstage of differentiation, producing a diffuse proliferation of large B lymphoid cells. The literature grounding also points to genetic, transcriptome, and epigenetic aspects in DLBCL, indicating biologic heterogeneity and molecularly defined subgroups. BCL6 is highlighted as an important regulator in DLBCL, consistent with a role for altered transcriptional control in disease biology.

The supplied grounding does not support specific risk factors for diffuse large B-cell lymphoma. It does indicate that genetic features and molecular classification are relevant to the disease, but not as established risk factors. EBV is discussed only at the level of EBV-related cancers overall, without disease-specific risk attribution here.

A widely recognized standard regimen is R-CHOP, which combines rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone. For relapsed or refractory disease, the literature highlights newer approaches including CAR-T cell therapy, bispecific T-cell engagers, immunomodulatory drugs, immune checkpoint inhibitors, monoclonal antibodies, antibody-drug conjugates, molecular pathway inhibitors, and epigenetic-modifying drugs. The grounding also specifically mentions axicabtagene ciloleucel and tisagenlecleucel as CAR-T therapies used in this setting.